• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Exelixis Inc (NQ: EXEL )

    25.96 -0.28 (-1.07%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,375,512
    Open 26.26
    Bid (Size) 25.92 (7)
    Ask (Size) 26.46 (1)
    Prev. Close 26.24
    Today's Range 25.93 - 26.37
    52wk Range 18.64 - 27.83
    Shares Outstanding 315,048,788
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
    For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. 
    Via Chartmill
    2 Growth Stocks to Buy With Less Than $100
    No need to break the bank to get in on these likely long-term winners. 
    Via The Motley Fool

    Performance

    YTD
    +8.48%
    +8.48%
    1 Month
    +0.89%
    +0.89%
    3 Month
    +15.22%
    +15.22%
    6 Month
    +9.40%
    +9.40%
    1 Year
    +16.99%
    +16.99%

    More News

    Read More
    A Closer Look at 5 Analyst Recommendations For Exelixis
    Via Benzinga
    Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
    From Exelixis, Inc.
    Via Business Wire
    NASDAQ:EXEL, an undervalued stock with good fundamentals.
    Via Chartmill
    In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
    Via Chartmill
    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
    From Exelixis, Inc.
    Via Business Wire
    3 Stocks to Buy for a Soft Landing, If There Is One
    Via MarketBeat
    Topics Economy
    Exposures Economy Interest Rates
    Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
    Via Investor's Business Daily
    Expert Outlook: Exelixis Through The Eyes Of 5 Analysts
    Via Benzinga
    Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
    Via Benzinga
    Exposures Product Safety
    US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Exelixis (EXEL) Q2 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
    Via Benzinga
    Topics Economy Stocks
    Exposures Economy US Equities
    Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
    From Exelixis, Inc.
    Via Business Wire
    US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
    From Exelixis, Inc.
    Via Business Wire
    In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
    Via Chartmill
    7 Cheap Biotech Stocks With Major Upside Potential
    Via InvestorPlace
    When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    Via Chartmill
    Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag.
    Via Chartmill
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.